Cited by 11,215Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAcute Ischemic Stroke Management

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Open access

Connolly, Stuart J., Ezekowitz, Michael D., Yusuf, Salim, Eikelboom, John, Oldgren, Jonas, Parekh, Amit, Pogue, Janice, Reilly, Paul A., Themeles, Ellison, Varrone, Jeanne, Wang, Susan, Alings, Marco, Xavier, Denis, Zhu, Jun, Diaz, Rafael, Lewis, Basil S., Darius, Harald, Diener, Hans-Christoph, Joyner, Campbell D., Wallentin, Lars·2009·New England Journal of Medicine

DOI 10.1056/nejmoa0905561

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. METHODS: In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted-dose warfarin. The median duration of the follow-up period was 2.0 years. The primary outcome was stroke or systemic embolism. RESULTS: Rates of the primary outcome were 1.69% per year in the warfarin group, as compared with 1.53% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.91; 95% confidence interval [CI], 0.74 to 1.11; P<0.001 for noninferiority) and 1.11% per year in the group that received 150 mg of dabigatran (relative risk, 0.66; 95% CI, 0.53 to 0.82; P<0.001 for superiority). The rate of major bleeding was 3.36% per year in the warfarin group, as compared with 2.71% per year in the group receiving 110 mg of dabigatran (P=0.003) and 3.11% per year in the group receiving 150 mg of dabigatran (P=0.31). The rate of hemorrhagic stroke was 0.38% per year in the warfarin group, as compared with 0.12% per year with 110 mg of dabigatran (P<0.001) and 0.10% per year with 150 mg of dabigatran (P<0.001). The mortality rate was 4.13% per year in the warfarin group, as compared with 3.75% per year with 110 mg of dabigatran (P=0.13) and 3.64% per year with 150 mg of dabigatran (P=0.051). CONCLUSIONS: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage. Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. (ClinicalTrials.gov number, NCT00262600.)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa0905561

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
(2006) · The Lancet · doi:10.1016/s0140-6736(06)68845-4 · Cited by 1,952
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation
Hart, R. G., Benavente, O., McBride, R., & Pearce, L. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-7-199910050-00003 · Cited by 1,636
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary
Fuster, V., Rydén, L., Cannom, D. S., Crijns, H. J. G. M., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Heuzey, J. L., Kay, G. N., Lowe, J. E., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.009 · Cited by 1,161
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,110
Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation
Hylek, E. M., Evans‐Molina, C., Shea, C., Henault, L. E., & Regan, S. (2007) · Circulation · doi:10.1161/circulationaha.106.653048 · Cited by 1,063
Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range
Connolly, S. J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M. G., Healey, J. S., & Yusuf, S. (2008) · Circulation · doi:10.1161/circulationaha.107.750000 · Cited by 870

Flagged first, then by citations

Show all 18 references

Sorted by citations

Items 901–1,000 of 1,022

Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
Westenbrink, B. D., Alings, M., Granger, C. B., Alexander, J. H., Lópes, R. D., Hylek, E. M., Thomas, L. E., WOJDYLA, D. M., Hanna, M., Keltai, M., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.12.008 · Cited by 91
Effects of dabigatran according to age in atrial fibrillation
Lauw, M. N., Eikelboom, J. W., Coppens, M., Wallentin, L. C., Yusuf, S., Ezekowitz, M. D., Oldgren, J., Nakamya, J., Wang, J., & Connolly, S. J. (2017) · Heart · doi:10.1136/heartjnl-2016-310358 · Cited by 88
Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions
Lund, L. H., Oldgren, J., & James, S. K. (2017) · Current Heart Failure Reports · doi:10.1007/s11897-017-0325-0 · Cited by 91
Quality of Pharmacist-Managed Anticoagulation Therapy in Long-Term Ambulatory Settings: A Systematic Review
Manzoor, B. S., Cheng, W., Lee, J. C., Uppuluri, E. M., & Nutescu, E. A. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017721241 · Cited by 95
Biomarker for Ischemic Stroke Using Metabolome: A Clinician Perspective
Sidorov, E., Sanghera, D. K., & Vanamala, J. K. P. (2019) · Journal of Stroke · doi:10.5853/jos.2018.03454 · Cited by 89
“5-hour window and endovascular thrombectomy within 24-hour window from the beginning of the stroke symptoms greatly improved outcomes;(3-5) newer anticoagulants prevent more strokes from atrial fibrillation.(6) In spite all that many important questions remain unanswered and many breakthrough are still to be made.”
Background
Continuous Anticoagulation and Cold Snare Polypectomy Versus Heparin Bridging and Hot Snare Polypectomy in Patients on Anticoagulants With Subcentimeter Polyps
Takeuchi, Y., Mabe, K., Shimodate, Y., Yoshii, S., Yamada, S., Iwatate, M., Kawamura, T., Hotta, K., Nagaike, K., Ikezawa, N., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0026 · Cited by 88
Atrial flutter: Clinical risk factors and adverse outcomes in the Framingham Heart Study
Rahman, F., Wang, N., Yin, X., Ellinor, P. T., Lubitz, S. A., LeLorier, P. A., McManus, D. D., SULLIVAN, L. M., Seshadri, S. S., Vasan, R. S., et al. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.07.031 · Cited by 90
Left Atrial Appendage Occlusion: Lessons Learned From Surgical and Transcatheter Experiences
Chatterjee, S., Alexander, J. C., Pearson, P. J., & Feldman, T. E. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2011.08.044 · Cited by 91
Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients
Firriolo, F., & Hupp, W. S. (2012) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2011.10.005 · Cited by 89
Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients with Atrial Fibrillation
Steinberg, B. A., Greiner, M. A., Hammill, B. G., Curtis, L. H., Benjamin, E. J., Heckbert, S. R., & Piccini, J. P. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12129 · Cited by 91
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience
Eikelboom, J. W., & Merli, G. J. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.003 · Cited by 90
Real-world adherence and persistence with direct oral anticoagulants in adults with atrial fibrillation
Manzoor, B. S., Lee, T. A., Sharp, L. K., Walton, S. M., Galanter, W. L., & Nutescu, E. A. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1989 · Cited by 88
Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial
Brambatti, M., Darius, H., Oldgren, J., Clemens, A., Noack, H., Brueckmann, M., Yusuf, S., Wallentin, L. C., Ezekowitz, M. D., Connolly, S. J., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.141 · Cited by 90
New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)
van Gorp, R. H., & Schurgers, L. J. (2015) · Nutrients · doi:10.3390/nu7115479 · Cited by 94
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study
Glund, S., Stangier, J., van Ryn, J., Schmohl, M., Moschetti, V., Haazen, W., Smet, M. D., Ganßer, D., Norris, S. H., Lang, B. J., et al. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0417-0 · Cited by 88
Effectiveness and Safety of Non–Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation
Hohnloser, S. H., Basic, E., Hohmann, C., & Näbauer, M. (2018) · Thrombosis and Haemostasis · doi:10.1160/th17-10-0733 · Cited by 90
Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease
Jain, N., & Reilly, R. F. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02170218 · Cited by 94
Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study
Piran, S., Traquair, H., Chan, N., Bhagirath, V. C., & Schulman, S. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12146 · Cited by 89
Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation
Arbel, R., Sergienko, R., Hammerman, A., Greenberg‐Dotan, S., Batat, E., Avnery, O. H., & Ellis, M. H. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.025 · Cited by 88
Atrial fibrillation as presenting sign of primary aldosteronism: results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study
Seccia, T. M., Letizia, C., Muiesan, M. L., Lerco, S., Cesari, M., Bisogni, V., Petramala, L., Maiolino, G., Volpin, R., & Rossi, G. P. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002250 · Cited by 89
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
Rutherford, O.-C. W., Jonasson, C., Ghanima, W., Söderdahl, F., & Halvorsen, S. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz086 · Cited by 92
“we did not find the reductions in stroke risk with dabigatran 150 mg and apixaban compared with warfarin that was shown in the RE-LY and ARISTOTLE trials.(5,6) This has, however, been the case in several previous real-world studies.”
Result
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/29/1560-4071-2020-4083 · Cited by 88
Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF
Harrington, J., Carnicelli, A., Hua, K., Wallentin, L. C., Patel, M. R., Hohnloser, S. H., Giugliano, R. P., Fox, K. A. A., Hijazi, Z., Lópes, R. D., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062752 · Cited by 92
Increases in Cerebral Atherosclerosis According to CHADS 2 Scores in Patients With Stroke With Nonvalvular Atrial Fibrillation
Kim, Y. D., Cha, M. J., Kim, J., Lee, D. H., Lee, H. S., Nam, C. M., Nam, H. S., & Heo, J. H. (2011) · Stroke · doi:10.1161/strokeaha.110.602987 · Cited by 88
Venous and arterial thrombosis – pathogenesis and the rationale for anticoagulation
Esmon, C. T., & Turpie, A. G. G. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-10-0683 · Cited by 90
Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives
Zou, J., Gao, P., Hao, X., Xu, H., Zhan, P., & Liu, X. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.097 · Cited by 89
New Oral Anticoagulants
Poulsen, B. K., Grove, E. L., & Husted, S. (2012) · Drugs · doi:10.2165/11635730-000000000-00000 · Cited by 87
Pacemaker-Detected Atrial Fibrillation in Patients With Pacemakers: Prevalence, Predictors, and Current Use of Oral Anticoagulation
Healey, J. S., Martin, J. L., Duncan, A., Connolly, S. J., Ha, A. H., Morillo, C. A., Nair, G. M., Eikelboom, J. W., Divakaramenon, S., & Dokainish, H. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.08.019 · Cited by 87
Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
Lip, G. Y. H., Kongnakorn, T., Phatak, H. M., Kuznik, A., Lanitis, T., Liu, L. Z., Iloeje, U. H., Hernandez, L. G., & Dorian, P. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.12.011 · Cited by 88
Laboratory Assessment of Novel Oral Anticoagulants: Method Suitability and Variability between Coagulation Laboratories
Helin, T., Pakkanen, A., Lassila, R., & Joutsi‐Korhonen, L. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.198788 · Cited by 88
Old Versus New Oral Anticoagulants: Focus on Pharmacology
Fareed, J., Thethi, I., & Hoppensteadt, D. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134633 · Cited by 90
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups
Lip, G. Y. H., Mitchell, S., Liu, X., Liu, L. Z., Phatak, H. M., Kachroo, S., & Batson, S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.11.084 · Cited by 90
Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation
Chan, Y., Yen, K., See, L., Chang, S., Wu, L., Lee, H., Tu, H., Yeh, Y., & Kuo, C.-T. (2016) · Stroke · doi:10.1161/strokeaha.115.011476 · Cited by 87
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Moneta, G. L. (2010) · Yearbook of Vascular Surgery · doi:10.1016/s0749-4041(09)79275-9 · Cited by 87
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study
Testa, S., Legnani, C., Tripodi, A., Paoletti, O., Pengo, V., Abbate, R., Bassi, L., Carraro, P., Cini, M., Paniccia, R., et al. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13486 · Cited by 87
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial
Lópes, R. D., Vora, A. N., Liaw, D., Granger, C. B., Darius, H., Goodman, S. G., Mehran, R., Windecker, S., & Alexander, J. H. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.03.001 · Cited by 89
Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation
Yu, H. T., Yang, P., Jang, E., Kim, T., Uhm, J., Kim, J., Pak, H., Lee, M., Lip, G. Y. H., & Joung, B. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014177 · Cited by 90
“4], and insurance claims for valve replacement or valvuloplasty) (n=8646), (2) those who ever underwent catheter ablation (n=5607), (3) those ever diagnosed with endstage renal disease (n=933), (4) no OAC or OAC use <30 days (n=717 946), (5) OAC use for acute coronary syndrome or deep vein thrombosis prophylaxis (n=41…”
Background
Thrombo-Embolism and Antithrombotic Therapy for Heart Failure in Sinus Rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis
Lip, G. Y. H., Ponikowski, P., Andreotti, F., Anker, S. D., Filippatos, G., Homma, S., Morais, J., Pullicino, P. M., Rasmussen, L. H., Marín, F. R., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs073 · Cited by 89
Left atrial flow velocity distribution and flow coherence using four‐dimensional FLOW MRI: A pilot study investigating the impact of age and Pre‐ and Postintervention atrial fibrillation on atrial hemodynamics
Fluckiger, J. U., Goldberger, J. J., Lee, D. C., Ng, J., Lee, R., Goyal, A., & Markl, M. (2013) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.23994 · Cited by 87
Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population‐based cohort study
Ording, A. G., Horváth–Puhó, E., Adelborg, K., Pedersen, L. H., Prandoni, P., & Sørensen, H. T. (2017) · Cancer Medicine · doi:10.1002/cam4.1054 · Cited by 87
Left Atrial Appendage Occlusion
Holmes, D. R., Lakkireddy, D., Whitlock, R. P., Waksman, R., & Mack, M. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.08.1631 · Cited by 88
Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment
Diener, H., Foerch, C., Riess, H. B., Röther, J., Schroth, G., & Weber, R. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70101-7 · Cited by 84
Meta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin Inhibitors
Artang, R., Rome, E., Nielsen, J. D., & Vidaillet, H. J., Jr. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.027 · Cited by 90
Perioperative management of anticoagulant and antiplatelet therapy
Tafur, A. J., & Douketis, J. D. (2017) · Heart · doi:10.1136/heartjnl-2016-310581 · Cited by 89
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
Oldgren, J., Steg, P. G., Hohnloser, S. H., Lip, G. Y. H., Kimura, T., Nordaby, M., Brueckmann, M., Kleine, E., ten Berg, J. M., Bhatt, D. L., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz059 · Cited by 89
Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants
Shahjouei, S., Tsivgoulis, G. K., Goyal, N., Sadighi, A., Mowla, A., Wang, M., Seiffge, D. J., & Zand, R. (2019) · Stroke · doi:10.1161/strokeaha.119.026426 · Cited by 92
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice
Roberti, R., Iannone, L. F., Palleria, C., Curcio, A., Rossi, M., Sciacqua, A., Armentaro, G., Vero, A., Manti, A., Cassano, V., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.684638 · Cited by 92
“Summary of Direct Oral Anticoagulants Studies in Cardiovascular Disorders Nowadays, several non-inferiority, randomized, double-blind, and international trials have been performed to evaluate DOACs’ efficacy in preventing stroke and systemic embolic events in patients with nonvalvular AF compared with warfarin and hav…”
BackgroundResult
A meta-analysis to determine the effect of anticoagulation on mortality in patients with blunt head trauma*
Batchelor, J. S., & Grayson, A. (2012) · British Journal of Neurosurgery · doi:10.3109/02688697.2011.650736 · Cited by 86
Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy
Rubboli, A. (2011) · World Journal of Cardiology · doi:10.4330/wjc.v3.i11.351 · Cited by 89
Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events
Hankey, G. J., & Eikelboom, J. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70038-7 · Cited by 87
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves
McKellar, S. H., Abel, S. A., Camp, C. L., Suri, R. M., Ereth, M. H., & Schaff, H. V. (2011) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.02.011 · Cited by 85
Atrial fibrillation in women: treatment
Ko, D., Rahman, F., Martins, M. A. P., Hylek, E. M., Ellinor, P. T., Schnabel, R. B., Benjamin, E. J., & Christophersen, I. E. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.171 · Cited by 87
Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation–Related Mild Ischemic Stroke
Hong, K., Kwon, S. U., Lee, S. H., Lee, J. S., Kim, Y., Song, T., Kim, Y. D., Park, M., Kim, E. G., Cha, J., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2161 · Cited by 89
Clinical and Radiographic Predictors of Intracerebral Hemorrhage Outcome
Al‐Mufti, F., Thabet, A. M., Singh, T., El-Ghanem, M. H., Amuluru, K., & Gandhi, C. D. (2018) · Interventional Neurology · doi:10.1159/000484571 · Cited by 84
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement
Guedeney, P., Mehran, R., Collet, J., Claessen, B. E. P. M., ten Berg, J. M., & Dangas, G. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.118.007411 · Cited by 87
Efficacy of Direct Acting Oral Anticoagulants in Treatment of Left Ventricular Thrombus
Fleddermann, A. M., Hayes, C. H., Magalski, A., & Main, M. L. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.009 · Cited by 87
Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
Grymonprez, M., Steurbaut, S., de Backer, T. L., Petrović, M., & Lahousse, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.583311 · Cited by 84
Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules
Loewen, P. S., & Dahri, K. M. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1267-3 · Cited by 85
A Prospective Study of Estimated Glomerular Filtration Rate and Outcomes in Patients With Atrial Fibrillation
Banerjee, A., Fauchier, L., Vourc’h, P., Andres, C. R., Taillandier, S., Halimi, J., & Lip, G. Y. H. (2013) · CHEST Journal · doi:10.1378/chest.13-2103 · Cited by 87
Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial
Bytzer, P. M., Connolly, S. J., Yang, S., Ezekowitz, M. D., Formella, S., Reilly, P. A., & Aisenberg, J. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.10.021 · Cited by 85
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score
Smith, J. G., Wieloch, M., Koul, S. M., Braun, O. Ö., Lumsden, J., Rydell, E., Öhman, J. N., Scherstén, F., Svensson, P. J., & van der Pals, J. (2012) · EuroIntervention · doi:10.4244/eijv8i6a105 · Cited by 85
Economic Evaluation of Percutaneous Left Atrial Appendage Occlusion, Dabigatran, and Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
Singh, S. M., Micieli, A., & Wijeysundera, H. C. (2013) · Circulation · doi:10.1161/circulationaha.112.000920 · Cited by 84
New oral anticoagulants and regional anaesthesia
Benzon, H. T., Avram, M. J., Green, D., & Bonow, R. O. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet401 · Cited by 87
The exact science of stroke thrombolysis and the quiet art of patient selection
Balami, J. S., Hadley, G., Sutherland, B. A., Karbalai, H., & Buchan, A. M. (2013) · Brain · doi:10.1093/brain/awt201 · Cited by 86
Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation
Canestaro, W. J., Patrick, A. R., Avorn, J., Ito, K., Matlin, O. S., Brennan, T. A., Shrank, W. H., & Choudhry, N. K. (2013) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000661 · Cited by 85
Rationale and design of the Chinese Atrial Fibrillation Registry Study
on behalf of the CAFR Investigators, Du, X., Ma, C., Wu, J., Li, S., Ning, M., Tang, R., Guo, X., Long, D., Yu, R., et al. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0308-1 · Cited by 84
Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke
Kapil, N., Datta, Y. H., Alakbarova, N., Bershad, E. M., Selim, M. H., Liebeskind, D. S., Bachour, O., Rao, G. H. R., & Divani, A. A. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616660762 · Cited by 86
Stroke in atrial fibrillation: Review of risk stratification and preventive therapy
Alshehri, A. (2019) · Journal of Family and Community Medicine · doi:10.4103/jfcm.jfcm_99_18 · Cited by 93
“Journal of Family and Community Medicine - Volume 26, Issue 2, May-August 2019 95 thromboembolism as well as increased bleeding associated with dabigatran.[23]”
Background
Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study
Beyer‐Westendorf, J., Tittl, L., Bistervels, I. M., Middeldorp, S., Schaefer, C., Paulus, W. E., Thomas, W., Kemkes‐Matthes, B., Marten, S., & Bornhäuser, M. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30327-6 · Cited by 92
Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry
Yamashita, T., Suzuki, S. S., Inoue, H., Akao, M., Atarashi, H., Ikeda, T., Okumura, K., Koretsune, Y., Shimizu, W., Tsutsui, H., et al. (2021) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcab025 · Cited by 85
Disparities in Anticoagulant Therapy Initiation for Incident Atrial Fibrillation by Race/Ethnicity Among Patients in the Veterans Health Administration System
Essien, U. R., Kim, N., Hausmann, L. R. M., Mor, M. K., Good, C. B., Magnani, J. W., Litam, T. M. A., Gellad, W. F., & Fine, M. J. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.14234 · Cited by 83
When Direct Oral Anticoagulants Should Not Be Standard Treatment
Bejjani, A., Khairani, C. D., Assi, A. A., Piazza, G., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Connors, J. M., Siegal, D. M., Barnes, G. D., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.038 · Cited by 89
Preferences for Oral Anticoagulants in Atrial Fibrillation: a Best–Best Discrete Choice Experiment
Ghijben, P., Lancsar, E., & Zavarsek, S. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0188-0 · Cited by 86
Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: The Retrospective Evaluation and Assessment of Therapies in AF (TREAT-AF) study
Turakhia, M. P., Hoang, D. D., Xu, X., Frayne, S. M., Schmitt, S. K., Yang, F., Phibbs, C. S., Than, C. T., Wang, P. J., & Heidenreich, P. A. (2012) · American Heart Journal · doi:10.1016/j.ahj.2012.10.010 · Cited by 84
Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation
Kent, A. P., Brueckmann, M., Fraessdorf, M., Connolly, S. J., Yusuf, S., Eikelboom, J. W., Oldgren, J., Reilly, P. A., Wallentin, L. C., & Ezekowitz, M. D. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.063 · Cited by 85
“The rationale and design of the RE-LY trial, as well as its primary outcomes were previously described (16,24).”
Background
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.10.019 · Cited by 85
Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at ‘moderate risk’ [CHADS2 score=1]: Simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice
Lip, G. Y. H. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-01-0038 · Cited by 84
FDA drug safety communications: a narrative review and clinical considerations for older adults
Marcum, Z. A., Vande Griend, J. P., & Linnebur, S. A. (2012) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2012.05.002 · Cited by 85
Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors
Grandhi, R., Newman, W. C., Zhang, X., Harrison, G. L., Moran, C. C., Okonkwo, D. O., & Ducruet, A. F. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.08.042 · Cited by 84
Benchmark for Time in Therapeutic Range in Venous Thromboembolism: A Systematic Review and Meta-Analysis
Erkens, P. M. G., Cate, H. T., Buller, H. R., & Prins, M. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042269 · Cited by 84
The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples
Butler, J., Malan, E., Chunilal, S. D., Tran, H., & Hapgood, G. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-04-0301 · Cited by 83
The APHRS's 2013 statement on antithrombotic therapy of patients with nonvalvular atrial fibrillation
Ogawa, S., Aonuma, K., Tse, H., Huang, D., Huang, J., Kalman, J. M., Kamakura, S., Nair, M., Shin, D., Stiles, M. K., et al. (2013) · Journal of Arrhythmia · doi:10.1016/j.joa.2013.03.002 · Cited by 83
Dabigatran, bleeding, and the regulators
Moore, T. J., Cohen, M. R., & Mattison, D. R. (2014) · BMJ · doi:10.1136/bmj.g4517 · Cited by 83
Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit
Gangireddy, S. R., Halperin, J. L., Fuster, V., & Reddy, V. Y. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs292 · Cited by 82
Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care
Kumar, S., de Lusignan, S., McGovern, A. P., Correa, A., Hriskova, M., Gatenby, P. A. C., Jones, S., Goldsmith, D. J. A., & Camm, A. J. (2018) · BMJ · doi:10.1136/bmj.k342 · Cited by 83
Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation
Lutsey, P. L., Norby, F. L., Ensrud, K. E., MacLehose, R. F., Diem, S. J., Chen, L. Y., & Alonso, Á. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.5679 · Cited by 84
Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases
Kermer, P., Eschenfelder, C. C., Diener, H., Grond, M., Abdalla, Y., Abraham, A., Althaus, K., Becks, G., Berrouschot, J., Berthel, J., et al. (2020) · International Journal of Stroke · doi:10.1177/1747493019895654 · Cited by 84
2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. Executive summary
Frendl, G., Sodickson, A., Chung, M. K., Waldo, A. L., Gersh, B. J., Tisdale, J. E., Calkins, H. G., Aranki, S. F., Kaneko, T., Cassivi, S. D., et al. (2014) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2014.06.037 · Cited by 83
Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation
Patti, G., Lucerna, M., Cavallari, I., Ricottini, E., Renda, G., Pecen, L., Romeo, F., Heuzey, J. L., Zamorano, J. L., Kirchhof, P. F., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.069 · Cited by 83
Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation
Savelieva, I., & Camm, A. J. (2013) · Clinical Cardiology · doi:10.1002/clc.22204 · Cited by 84
Prise en charge des complications hémorragiques graves et de la chirurgie en urgence chez les patients recevant un anticoagulant oral anti-IIa ou anti-Xa direct. Propositions du Groupe d’intérêt en Hémostase Périopératoire (GIHP) - mars 2013
Pernod, G., Albaladejo, P., Godiér, A., Samama, C. M., Susen, S., Gruel, Y., Blais, N., Fontana, P., Cohen, A. A., Llau, J. V., et al. (2013) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2013.04.016 · Cited by 82
Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation
Alberts, M. J., Eikelboom, J. W., & Hankey, G. J. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70258-2 · Cited by 80
Atrial Fibrillation in CKD: Balancing the Risks and Benefits of Anticoagulation
Ng, K. P., Edwards, N. C., Lip, G. Y. H., Townend, J., & Ferro, C. J. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.02.381 · Cited by 82
Prediction of Warfarin Dose: Why, When and How?
Eriksson, N., & Wadelius, M. (2012) · Pharmacogenomics · doi:10.2217/pgs.11.184 · Cited by 88
Cost-Effectiveness of Outpatient Cardiac Monitoring to Detect Atrial Fibrillation After Ischemic Stroke
Kamel, H., Hegde, M., Johnson, D. R., Gage, B. F., & Johnston, S. C. (2010) · Stroke · doi:10.1161/strokeaha.110.582437 · Cited by 81
Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: A nationwide cohort study of 9519 patients
Andersson, T., Magnuson, A., Bryngelsson, I.-L., Frøbert, O., Henriksson, K. M., Edvardsson, N., & Poçi, D. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.092 · Cited by 68
Cardiovascular Disease in Women
Stock, E. O., & Redberg, R. (2012) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2012.07.001 · Cited by 65
Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS 2 to the CHA 2 DS 2 -VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry’s Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry
Katz, D. F., Maddox, T. M., Turakhia, M., Gehi, A., O’Brien, E. C., Lubitz, S. A., Turchin, A., Doros, G., Lei, L., Varosy, P., et al. (2017) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003476 · Cited by 64
Management of acute stroke in patients taking novel oral anticoagulants
Hankey, G. J., Norrving, B., Hacke, W., & Steiner, T. (2014) · International Journal of Stroke · doi:10.1111/ijs.12295 · Cited by 63
Targeted thromboelastographic (TEG) blood component and pharmacologic hemostatic therapy in traumatic and acquired coagulopathy
Walsh, M., Fritz, S., Hake, D., Son, M., Greve, S., Jbara, M., Chitta, S., Fritz, B., Miller, A., K Bader, M., et al. (2016) · Current Drug Targets · doi:10.2174/1389450117666160310153211 · Cited by 58

Authors: Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B. S., Darius, H., Diener, H.-C., Joyner, C. D., & Wallentin, L.
Affiliations: Population Health Research Institute (CA)
Lankenau Institute for Medical Research (US)
Uppsala University (SE)
Boehringer Ingelheim (United States) (US)
Werkgroep Cardiologische centra Nederland (NL)
St. John's National Academy of Health Sciences (IN)
Fu Wai Hospital (CN)
Carmel Medical Center (IL)
Vivantes Klinikum (DE)
Sunnybrook Health Science Centre (CA)
ORCID: Connolly, Stuart J.
Ezekowitz, Michael D.
Yusuf, Salim
Eikelboom, John
Oldgren, Jonas
Parekh, Amit
Alings, Marco
Xavier, Denis
Zhu, Jun
Lewis, Basil S.
Wallentin, Lars
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2009-09-17
Volume: 361
Issue: 12
Pages: 1139-1151
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa0905561
OpenAlex: W2136489990
Cited by: 11,215
References: 18
Citations by year: 2026: 219 · 2025: 318 · 2024: 395 · 2023: 489 · 2022: 507 · 2021: 662 · 2020: 745 · 2019: 669 · 2018: 775 · 2017: 799 · 2016: 864 · 2015: 923 · 2014: 874 · 2013: 1000 · 2012: 915
FWCI: 419.63
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
UWA Profiles and Research Repository (UWA) (publishedVersion, other-oa)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
Minerva Access (University of Melbourne) (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
Figshare (submittedVersion)
UnissResearch (Università degli Studi di Sassari) (submittedVersion)
Open Repository and Bibliography (University of Liège) (submittedVersion)
Funders: Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
GlaxoSmithKline
Sanofi
Daiichi-Sankyo
Eisai
Servier
Cilag
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords: dabigatran, warfarin, atrial fibrillation, direct thrombin inhibitors, oral anticoagulants, stroke prevention, systemic embolism, major bleeding, hemorrhagic stroke, non-inferiority, mortality, fixed-dose dosing, bleeding risk stratification, anticoagulation
MeSH terms: Dabigatran, Aged, Anticoagulants, Atrial Fibrillation, Benzimidazoles, Double-Blind Method, Dyspepsia, Embolism, Female, Follow-Up Studies, Hemorrhage, Humans, Liver, Male, Middle Aged, Myocardial Infarction, Prodrugs, Pyridines, Warfarin, Chi-Square Distribution, Proportional Hazards Models, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks